Guanidinoacetate methyltransferase deficiency

Last updated
Guanidinoacetate methyltransferase deficiency
Other namesGAMT deficiency
Creatine neutral.png
Specialty Medical genetics
CausesDeficiency of guanidinoacetate methyltransferase enzyme
Diagnostic method Genetic testing, magnetic resonance spectroscopy, blood and urine testing
TreatmentDietary adjustment and creatine supplementation

Guanidinoacetate methyltransferase deficiency (GAMT deficiency) is an autosomal recessive [1] cerebral creatine deficiency that primarily affects the nervous system and muscles. It is the first described disorder of creatine metabolism, and results from deficient activity of guanidinoacetate methyltransferase, an enzyme involved in the synthesis of creatine. [2] Clinically, affected individuals often present with hypotonia, seizures and developmental delay. Diagnosis can be suspected on clinical findings, and confirmed by specific biochemical tests, brain magnetic resonance spectroscopy, or genetic testing. Biallelic pathogenic variants in GAMT are the underlying cause of the disorder. After GAMT deficiency is diagnosed, it can be treated by dietary adjustments, including supplementation with creatine. Treatment is highly effective if started early in life. If treatment is started late, it cannot reverse brain damage which has already taken place.

Contents

Signs and symptoms

Individuals with GAMT deficiency appear normal at birth. Shortly after birth, infants may start to show signs, as the consequences of decreased creatine levels in their body become more apparent. These clinical findings are relatively non-specific, and do not immediately suggest a disorder of creatine metabolism. Common clinical findings, as with other cerebral creatine deficiencies, include developmental delay (both intellectual and motor), seizures and hypotonia. [3] [4] Speech delay, autism, and self-injurious behaviour have also been described. [5]

Depiction showing normal creatine production (top) and disrupted creatine production in GAMT deficiency (bottom) Disrupted creatine production in GAMT deficiency.jpg
Depiction showing normal creatine production (top) and disrupted creatine production in GAMT deficiency (bottom)

Genetics

GAMT (EC 2.1.1.2) catalyzes the second step in the creatine biosynthetic pathway. CreatineSynthesis(en).png
GAMT (EC 2.1.1.2) catalyzes the second step in the creatine biosynthetic pathway.

Biallelic pathogenic variants in GAMT are associated with guanidinoacetate methyltransferase deficiency. This gene codes for the enzyme guanidinoacetate methyltransferase (GAMT), which participates in the two-step synthesis of the compound creatine from amino acids glycine, arginine and methionine. Specifically, GAMT controls the second step of the sequence, in which creatine is produced from another compound called guanidinoacetate. [6] The effects of GAMT deficiency are most severe in organs and tissues that require large amounts of energy, such as the brain and muscles.[ citation needed ]

This disorder is inherited in an autosomal recessive manner, which means the causative gene is located on an autosome, and two defective copies of the gene – one from each parent – are required to inherit the disorder. The parents both carry one pathogenic variant, however they are not affected by the disorder. As carriers, the residual activity of approximately 50% is enough to avoid clinical complications. [3] Unaffected siblings of an affected individual have a 2/3 chance of being carriers. [3]

Diagnosis

GAMT deficiency can be suspected from clinical findings, although clinical findings are not suggestive of a specific diagnosis. Laboratory testing of plasma and urine will show decreased levels of creatine and increased levels of guanidinoacetate. Non-specific elevations of metabolites on urine testing, such as organic acid analysis, that are normalized to creatinine may be observed. For these tests, the excretion of urine metabolites is not elevated, but appears elevated due to unusually low creatinine values. [4] Specific diagnostic testing for GAMT deficiency relies on the measurement of guanidinoacetate and creatine in urine and plasma. Increased levels of guanidinoacetate and decreased levels of creatine can suggest a diagnosis. [4] Confirmatory testing can include enzyme assays to directly measure guanidinoacetate methyltransferase activity or molecular testing of GAMT. Brain magnetic resonance spectroscopy will show decreased levels of creatine, in affected individuals, however this finding is seen in all three cerebral creatine deficiencies, and needs to be followed up to identify the specific defect. [4]

Treatment is most effective for GAMT deficiency with early diagnosis, however the non-specific clinical findings mean there is often a delay in diagnosis. Due to the efficacy of treatment and the delay in diagnosis, GAMT deficiency has been recommended for newborn screening by the United States Advisory Committee on Heritable Disorders in Newborns and Children. Newborn screening assays measure the amount of guanidinoacetate in a dried blood spot using tandem mass spectrometry. Abnormal results from a newborn screening test still need to be confirmed by testing in plasma or urine. [7]

GAMT deficiency was nominated to be included in the list of disorders recommended for screening in the United States in 2016. It was initially not recommended for inclusion, as studies completed at the time could not demonstrate that a case could be reliably identified in a newborn screening setting. [8] Utah started screening for GAMT deficiency in all newborns in 2015. New York started screening newborns in late 2018. [9] In 2020, a GAMT-positive infant was identified via newborn screening in Utah, [10] thus providing evidence that a case could be identified from newborn screening. A second infant was identified in New York in 2021. [10] In 2022, a federal advisory committee voted to include GAMT in the Recommended Universal Screening Panel starting in January 2023. [11] California began screening for GAMT in 2024. [12]

Treatment

Treatment of GAMT deficiency focuses on restoration of depleted brain creatine with creatine supplementation in pharmacologic doses, and removal of toxic intermediates via ornithine supplementation. [8] All patients are reported to benefit by this treatment, with improvements in muscular hypotonia, dyskinesia, social contact, alertness and behavior. Seizures appear to reduce more with dietary arginine restriction and ornithine supplementation. Despite treatment, none of the patients have been reported to return to completely normal developmental level, if significant damage had taken place before treatment. Prior to the addition of GAMT deficiency to newborn screening panels, younger siblings of affected individuals may have been tested at birth and treated early. This early treatment can result in outcomes that are very close to normal. [8]

Related Research Articles

<span class="mw-page-title-main">Galactosemia</span> Medical condition

Galactosemia is a rare genetic metabolic disorder that affects an individual's ability to metabolize the sugar galactose properly. Galactosemia follows an autosomal recessive mode of inheritance that confers a deficiency in an enzyme responsible for adequate galactose degradation.

<span class="mw-page-title-main">Methylmalonic acidemias</span> Medical condition

Methylmalonic acidemias, also called methylmalonic acidurias, are a group of inherited metabolic disorders, that prevent the body from properly breaking down proteins and fats. This leads to a buildup of a toxic level of methylmalonic acid in body liquids and tissues. Due to the disturbed branched-chain amino acids (BCAA) metabolism, they are among the classical organic acidemias.

Hypotonia is a state of low muscle tone, often involving reduced muscle strength. Hypotonia is not a specific medical disorder, but a potential manifestation of many different diseases and disorders that affect motor nerve control by the brain or muscle strength. Hypotonia is a lack of resistance to passive movement, whereas muscle weakness results in impaired active movement. Central hypotonia originates from the central nervous system, while peripheral hypotonia is related to problems within the spinal cord, peripheral nerves and/or skeletal muscles. Severe hypotonia in infancy is commonly known as floppy baby syndrome. Recognizing hypotonia, even in early infancy, is usually relatively straightforward, but diagnosing the underlying cause can be difficult and often unsuccessful. The long-term effects of hypotonia on a child's development and later life depend primarily on the severity of the muscle weakness and the nature of the cause. Some disorders have a specific treatment but the principal treatment for most hypotonia of idiopathic or neurologic cause is physical therapy and/or occupational therapy for remediation.

<span class="mw-page-title-main">Lesch–Nyhan syndrome</span> Rare genetic disorder

Lesch–Nyhan syndrome (LNS) is a rare inherited disorder caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). This deficiency occurs due to mutations in the HPRT1 gene located on the X chromosome. LNS affects about 1 in 380,000 live births. The disorder was first recognized and clinically characterized by American medical student Michael Lesch and his mentor, pediatrician William Nyhan, at Johns Hopkins.

<span class="mw-page-title-main">Menkes disease</span> X-linked recessive copper-transport disorder

Menkes disease (MNK), also known as Menkes syndrome, is an X-linked recessive disorder caused by mutations in genes coding for the copper-transport protein ATP7A, leading to copper deficiency. Characteristic findings include kinky hair, growth failure, and nervous system deterioration. Like all X-linked recessive conditions, Menkes disease is more common in males than in females. The disorder was first described by John Hans Menkes in 1962.

Inborn errors of metabolism form a large class of genetic diseases involving congenital disorders of enzyme activities. The majority are due to defects of single genes that code for enzymes that facilitate conversion of various substances (substrates) into others (products). In most of the disorders, problems arise due to accumulation of substances which are toxic or interfere with normal function, or due to the effects of reduced ability to synthesize essential compounds. Inborn errors of metabolism are often referred to as congenital metabolic diseases or inherited metabolic disorders. Another term used to describe these disorders is "enzymopathies". This term was created following the study of biodynamic enzymology, a science based on the study of the enzymes and their products. Finally, inborn errors of metabolism were studied for the first time by British physician Archibald Garrod (1857–1936), in 1908. He is known for work that prefigured the "one gene–one enzyme" hypothesis, based on his studies on the nature and inheritance of alkaptonuria. His seminal text, Inborn Errors of Metabolism, was published in 1923.

<span class="mw-page-title-main">Maple syrup urine disease</span> Autosomal recessive metabolic disorder

Maple syrup urine disease (MSUD) is a rare, inherited metabolic disorder that affects the body’s ability to metabolize amino acids due to a deficiency in the activity of the branched-chain alpha-ketoacid dehydrogenase (BCKAD) complex. It particularly affects the metabolism of amino acids- leucine, isoleucine, and valine. With MSUD, the body is not able to properly break down these amino acids, therefore leading to the amino acids to build up in urine and become toxic. The condition gets its name from the distinctive sweet odor of affected infants' urine and earwax due to the buildup of these amino acids.

<span class="mw-page-title-main">Systemic primary carnitine deficiency</span> Medical condition

Systemic primary carnitine deficiency (SPCD) is an inborn error of fatty acid transport caused by a defect in the transporter responsible for moving carnitine across the plasma membrane. Carnitine is an important amino acid for fatty acid metabolism. When carnitine cannot be transported into tissues, fatty acid oxidation is impaired, leading to a variety of symptoms such as chronic muscle weakness, cardiomyopathy, hypoglycemia and liver dysfunction. The specific transporter involved with SPCD is OCTN2, coded for by the SLC22A5 gene located on chromosome 5. SPCD is inherited in an autosomal recessive manner, with mutated alleles coming from both parents.

<span class="mw-page-title-main">3-Methylcrotonyl-CoA carboxylase deficiency</span> Medical condition

3-Methylcrotonyl-CoA carboxylase deficiency also known as 3-Methylcrotonylglycinuria is an inborn error of leucine metabolism and is inherited through an autosomal recessive fashion. 3-Methylcrotonyl-CoA carboxylase deficiency is caused by mutations in the MCCC1 gene, formerly known as MMCA, or the MCCC2 gene, formerly known as MCCB. MCCC1 encodes the a-subunits of 3-methylcrotonyl-CoA carboxylase while MCCC2 encodes the b-subunits. The clinical presentation of 3-Methylcrotonyl-CoA carboxylase deficiency is varied, even within members of the same family.

<span class="mw-page-title-main">Purine nucleoside phosphorylase deficiency</span> Medical condition

Purine nucleoside phosphorylase deficiency is a rare autosomal recessive metabolic disorder which results in immunodeficiency.

<span class="mw-page-title-main">Arginine:glycine amidinotransferase</span> Enzyme

L-Arginine:glycine amidinotransferase is the enzyme that catalyses the transfer of an amidino group from L-arginine to glycine. The products are L-ornithine and glycocyamine, also known as guanidinoacetate, the immediate precursor of creatine. Creatine and its phosphorylated form play a central role in the energy metabolism of muscle and nerve tissues. Creatine is in highest concentrations in the skeletal muscle, heart, spermatozoa and photoreceptor cells. Creatine helps buffer the rapid changes in ADP/ATP ratio in muscle and nerve cells during active periods. Creatine is also synthesized in other tissues, such as pancreas, kidneys, and liver, where amidinotransferase is located in the cytoplasm, including the intermembrane space of the mitochondria, of the cells that make up those tissues.

<span class="mw-page-title-main">Cerebral creatine deficiency</span> Medical condition

Cerebral creatine deficiencies are a small group of inherited disorders that result from defects in creatine biosynthesis and utilization. Commonly affected tissues include the brain and muscles. There are three distinct CCDs. The most common is creatine transporter defect (CTD), an X-linked disorder caused by pathogenic variants in SLC6A8. The main symptoms of CTD are intellectual disability and developmental delay, and these are caused by a lack of creatine in the brain, due to the defective transporter. There are also two enzymatic defects of creatine biosynthesis, arginine:glycine amidinotransferase deficiency, caused by variants in GATM and guanidinoacetate methyltransferase deficiency, caused by variants in GAMT. The single enzyme defects are both inherited in an autosomal recessive manner.

<span class="mw-page-title-main">Guanidinoacetate N-methyltransferase</span> Mammalian protein found in Homo sapiens

Guanidinoacetate N-methyltransferase is an enzyme that catalyzes the chemical reaction and is encoded by gene GAMT located on chromosome 19p13.3.

Organic acidemia is a term used to classify a group of metabolic disorders which disrupt normal amino acid metabolism, particularly branched-chain amino acids, causing a buildup of acids which are usually not present.

Global developmental delay is an umbrella term used when children are significantly delayed in two or more areas of development. It can be diagnosed when a child is delayed in one or more milestones, categorised into motor skills, speech, cognitive skills, and social and emotional development. There is usually a specific condition which causes this delay, such as Cerebral Palsy, Fragile X syndrome or other chromosomal abnormalities. However, it is sometimes difficult to identify this underlying condition.

<span class="mw-page-title-main">Ornithine aminotransferase deficiency</span> Medical condition

Ornithine aminotransferase deficiency is an inborn error of ornithine metabolism, caused by decreased activity of the enzyme ornithine aminotransferase. Biochemically, it can be detected by elevated levels of ornithine in the blood. Clinically, it presents initially with poor night vision, which slowly progresses to total blindness. It is believed to be inherited in an autosomal recessive manner. Approximately 200 known cases have been reported in the literature. The incidence is highest in Finland, estimated at 1:50,000.

<span class="mw-page-title-main">Creatine transporter defect</span> Medical condition

Creatine transporter deficiency (CTD) is an inborn error of creatine metabolism in which creatine is not properly transported to the brain and muscles due to defective creatine transporters. CTD is an X-linked disorder caused by mutation in SLC6A8. SLC6A8 is located at Xq28. Hemizygous males with CTD express speech and behavior abnormalities, intellectual disabilities, development delay, seizures, and autistic behavior. Heterozygous females with CTD generally express fewer, less severe symptoms. CTD is one of three different types of cerebral creatine deficiency (CCD). The other two types of CCD are guanidinoacetate methyltransferase (GAMT) deficiency and L-arginine:glycine amidinotransferase (AGAT) deficiency. Clinical presentation of CTD is similar to that of GAMT and AGAT deficiency. CTD was first identified in 2001 with the presence of a hemizygous nonsense change in SLC6A8 in a male patient.

<span class="mw-page-title-main">Sengers syndrome</span> Medical condition

Sengers syndrome is a rare autosomal recessive mitochondrial disease characterised by congenital cataract, hypertrophic cardiomyopathy, muscle weakness and lactic acidosis after exercise. Biallelic pathogenic mutations in the AGK gene, which encodes the acylglycerol kinase enzyme, cause Sengers syndrome. In addition, heart disease and muscle disease are prevalent, meaning that life expectancy is short for many patients.

<span class="mw-page-title-main">Arginine:glycine amidinotransferase deficiency</span> Medical condition

Arginine:glycine amidinotransferase deficiency or AGAT deficiency is an autosomal recessive cerebral creatine deficiency caused by a deficiency of the enzyme arginine:glycine amidinotransferase. This enzyme deficiency results in decreased creatine synthesis, and is caused by biallelic pathogenic variants in GATM. Individuals with AGAT deficiency are intellectually disabled and have muscle weakness. The symptoms of AGAT deficiency are caused by the lack of creatine in specific tissues, most notably muscle and brain. Oral creatine supplementation can be used to treat AGAT deficiency, with early intervention providing the best results. All creatine deficiencies are rare, and there have been fewer than 20 individuals reported in medical literature with AGAT deficiency. This disorder was first described in 2000.

<span class="mw-page-title-main">Acyl-CoA oxidase deficiency</span> Medical condition

Acyl-CoA oxidase deficiency is a rare disorder that leads to significant damage and deterioration of nervous system functions (neurodegeneration). It is caused by pathogenic variants in ACOX1, which codes for the production of an enzyme called peroxisomal straight-chain acyl-CoA oxidase (ACOX1). This specific enzyme is responsible for the breakdown of very long chain fatty acids (VLCFAs).

References

  1. ↑ Schulze, Andreas (2003). "Creatine deficiency syndromes". Molecular and Cellular Biochemistry. 244 (1/2): 143–150. doi:10.1023/A:1022443503883. ISSN   0300-8177. PMID   12701824. S2CID   25056424.
  2. ↑ Stöckler, S; Isbrandt, D; Hanefeld, F; Schmidt, B; Von Figura, K (1 May 1996). "Guanidinoacetate methyltransferase deficiency: the first inborn error of creatine metabolism in man" (Free full text). American Journal of Human Genetics. 58 (5): 914–22. ISSN   0002-9297. PMC   1914613 . PMID   8651275.
  3. 1 2 3 "612736 CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2". Johns Hopkins University. Retrieved 2019-01-05.
  4. 1 2 3 4 Schulze, Andreas (2009). "Creatine Deficiency Syndromes". In Sarafoglou, Kiriakie; Hoffmann, Georg F.; Roth, Karl S. (eds.). Pediatric Endocrinology and Inborn Errors of Metabolism (1st ed.). New York: McGraw-Hill Medical. pp. 153–161. ISBN   978-0-07-143915-2.
  5. ↑ Braissant, Olivier; Henry, Hugues; Béard, Elidie; Uldry, Joséphine (2011). "Creatine deficiency syndromes and the importance of creatine synthesis in the brain" (PDF). Amino Acids. 40 (5): 1315–1324. doi:10.1007/s00726-011-0852-z. ISSN   0939-4451. PMID   21390529. S2CID   13755292.
  6. ↑ Clark, Joseph F.; Cecil, Kim M. (2014). "Diagnostic methods and recommendations for the cerebral creatine deficiency syndromes". Pediatric Research. 77 (3): 398–405. doi: 10.1038/pr.2014.203 . ISSN   0031-3998. PMID   25521922. S2CID   6720075.
  7. ↑ Ombrone D, Giocaliere E, Forni G, Malvagia S, la Marca G (2016). "Expanded newborn screening by mass spectrometry: New tests, future perspectives" (PDF). Mass Spectrom Rev. 35 (1): 71–84. Bibcode:2016MSRv...35...71O. doi:10.1002/mas.21463. hdl: 2158/1010572 . PMID   25952022. S2CID   21933819. Archived from the original (PDF) on 2022-03-29. Retrieved 2019-09-02.
  8. 1 2 3 Chen, Daphne (2016-11-02). "Utah mom, doctors push to add rare disorder to national newborn screening panel". Deseret News, Utah. Retrieved 2019-02-18.
  9. ↑ "Newborn Screening Program". Association for Creatine Deficiencies. Retrieved 2019-05-05.
  10. 1 2 Hart, Kim; Rohrwasser, Andreas; Wallis, Heidi; Golsan, Heather; Shao, Jianyin; Anderson, Taylor; Wang, Xiaoli; Szabo-Fresnais, Nicolas; Morrissey, Mark; Kay, Denise M.; Wojcik, Matthew; Galvin-Parton, Patricia A.; Longo, Nicola; Caggana, Michele; Pasquali, Marzia (2021-09-01). "Prospective identification by neonatal screening of patients with guanidinoacetate methyltransferase deficiency". Molecular Genetics and Metabolism. 134 (1): 60–64. doi:10.1016/j.ymgme.2021.07.012. ISSN   1096-7192.
  11. ↑ Ream, Margie A.; Lam, Wendy K. K.; Grosse, Scott D.; Ojodu, Jelili; Jones, Elizabeth; Prosser, Lisa A.; Rose, Angela M.; Comeau, Anne Marie; Tanksley, Susan; Powell, Cynthia M.; Kemper, Alex R. (2023-08-01). "Evidence and Recommendation for Guanidinoacetate Methyltransferase Deficiency Newborn Screening". Pediatrics. 152 (2): e2023062100. doi:10.1542/peds.2023-062100. ISSN   1098-4275. PMC   10527896 . PMID   37465909.
  12. ↑ "NBS Program Disorders Detectable". www.cdph.ca.gov. Retrieved 2024-08-20.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.